{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:55:46Z","timestamp":1788184546481,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic interventions with proven efficacy in heart failure with reduced ejection fraction (HFrEF) have been unsuccessful in heart failure with preserved ejection fraction (HFpEF). The modifiable risk factor with the greatest impact on the development of HFpEF is hypertension. The objectives of this study were to establish a murine model of HFpEF associated with hypertension and to evaluate the effect of apo A-I<jats:sub>Milano<\/jats:sub> nanoparticles (MDCO-216) on established HFpEF in this model. Subcutaneous infusion of angiotensin II in combination with 1% NaCl in the drinking water was started at the age of 12 weeks in male C57BL\/6\u2009N mice and continued for the entire duration of the experiment. Treatment with MDCO-216 partially reversed established cardiac hypertrophy, cardiomyocyte hypertrophy, capillary rarefaction, and perivascular fibrosis in this model. Pressure-volume loop analysis was consistent with HFpEF in hypertension mice as evidenced by the preserved ejection fraction and a significant reduction of cardiac output (7.78\u2009\u00b1\u20090.56\u2009ml\/min versus 10.5\u2009\u00b1\u20090.7\u2009ml\/min; p\u2009&lt;\u20090.01) and of the peak filling rate (p\u2009&lt;\u20090.05). MDCO-216 completely reversed cardiac dysfunction and abolished heart failure as evidenced by the normal lung weight and normal biomarkers of heart failure. In conclusion, apo A-I<jats:sub>Milano<\/jats:sub> nanoparticles constitute an effective treatment for established hypertension-associated HFpEF.<\/jats:p>","DOI":"10.1038\/s41598-020-65255-y","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:02:32Z","timestamp":1589968952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension"],"prefix":"10.1038","volume":"10","author":[{"given":"Mudit","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilayaraja","family":"Muthuramu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"65255_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","volume":"50","author":"GC Fonarow","year":"2007","unstructured":"Fonarow, G. C. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50, 768\u2013777, https:\/\/doi.org\/10.1016\/j.jacc.2007.04.064 (2007).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","volume":"5","author":"SM Dunlay","year":"2012","unstructured":"Dunlay, S. M., Roger, V. L., Weston, S. A., Jiang, R. & Redfield, M. M. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5, 720\u2013726, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.966366 (2012).","journal-title":"Circ Heart Fail"},{"key":"65255_CR3","doi-asserted-by":"publisher","unstructured":"Borlaug, B. A. & Redfield, M. M. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123, 2006-2013; discussion 2014, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.954388 (2011).","DOI":"10.1161\/CIRCULATIONAHA.110.954388"},{"key":"65255_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus, W. J. & Tschope, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62, 263\u2013271, https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092 (2013).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCHEARTFAILURE.112.972265","volume":"5","author":"WC Little","year":"2012","unstructured":"Little, W. C. & Zile, M. R. HFpEF: cardiovascular abnormalities not just comorbidities. Circ Heart Fail 5, 669\u2013671, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.972265 (2012).","journal-title":"Circ Heart Fail"},{"key":"65255_CR6","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.106.659763","volume":"115","author":"CS Lam","year":"2007","unstructured":"Lam, C. S. et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115, 1982\u20131990, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.659763 (2007).","journal-title":"Circulation"},{"key":"65255_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jacc.2003.11.040","volume":"43","author":"M Klapholz","year":"2004","unstructured":"Klapholz, M. et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 43, 1432\u20131438, https:\/\/doi.org\/10.1016\/j.jacc.2003.11.040 (2004).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jacc.2006.08.050","volume":"49","author":"V Melenovsky","year":"2007","unstructured":"Melenovsky, V. et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling\/dysfunction. J Am Coll Cardiol 49, 198\u2013207, https:\/\/doi.org\/10.1016\/j.jacc.2006.08.050 (2007).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jacc.2009.05.013","volume":"54","author":"BA Borlaug","year":"2009","unstructured":"Borlaug, B. A., Lam, C. S., Roger, V. L., Rodeheffer, R. J. & Redfield, M. M. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54, 410\u2013418, https:\/\/doi.org\/10.1016\/j.jacc.2009.05.013 (2009).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","volume":"275","author":"D Levy","year":"1996","unstructured":"Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B. & Ho, K. K. The progression from hypertension to congestive heart failure. Jama 275, 1557\u20131562, https:\/\/doi.org\/10.1001\/jama.1996.03530440037034 (1996).","journal-title":"Jama"},{"key":"65255_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker, G. M. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342, 1077\u20131084, https:\/\/doi.org\/10.1056\/NEJM200004133421502 (2000).","journal-title":"N Engl J Med"},{"key":"65255_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mcna.2016.08.013","volume":"101","author":"W Nadruz","year":"2017","unstructured":"Nadruz, W., Shah, A. M. & Solomon, S. D. Diastolic Dysfunction and Hypertension. Med Clin North Am 101, 7\u201317, https:\/\/doi.org\/10.1016\/j.mcna.2016.08.013 (2017).","journal-title":"Med Clin North Am"},{"key":"65255_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.mcna.2009.02.013","volume":"93","author":"A Verma","year":"2009","unstructured":"Verma, A. & Solomon, S. D. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 93, 647\u2013664, https:\/\/doi.org\/10.1016\/j.mcna.2009.02.013 (2009).","journal-title":"Med Clin North Am"},{"key":"65255_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jacc.2013.10.063","volume":"63","author":"SH Wan","year":"2014","unstructured":"Wan, S. H., Vogel, M. W. & Chen, H. H. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 63, 407\u2013416, https:\/\/doi.org\/10.1016\/j.jacc.2013.10.063 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","volume":"289","author":"MM Redfield","year":"2003","unstructured":"Redfield, M. M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama 289, 194\u2013202, https:\/\/doi.org\/10.1001\/jama.289.2.194 (2003).","journal-title":"Jama"},{"key":"65255_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/oxfordjournals.eurheartj.a059783","volume":"11","author":"P Verdecchia","year":"1990","unstructured":"Verdecchia, P. et al. Prevalence and determinants of left ventricular diastolic filling abnormalities in an unselected hypertensive population. Eur Heart J 11, 679\u2013691, https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a059783 (1990).","journal-title":"Eur Heart J"},{"key":"65255_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/eurheartj\/ehi019","volume":"26","author":"G de Simone","year":"2005","unstructured":"de Simone, G. et al. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J 26, 1039\u20131045, https:\/\/doi.org\/10.1093\/eurheartj\/ehi019 (2005).","journal-title":"Eur Heart J"},{"key":"65255_CR18","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy, C. W. et al. ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62, e147\u2013239, https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019 (2013).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cpcardiol.2015.12.002","volume":"41","author":"YN Reddy","year":"2016","unstructured":"Reddy, Y. N. & Borlaug, B. A. Heart Failure With Preserved Ejection Fraction. Curr Probl Cardiol 41, 145\u2013188, https:\/\/doi.org\/10.1016\/j.cpcardiol.2015.12.002 (2016).","journal-title":"Curr Probl Cardiol"},{"key":"65255_CR20","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","volume":"375","author":"MM Redfield","year":"2016","unstructured":"Redfield, M. M. Heart Failure with Preserved Ejection Fraction. N Engl J Med 375, 1868\u20131877, https:\/\/doi.org\/10.1056\/NEJMcp1511175 (2016).","journal-title":"N Engl J Med"},{"key":"65255_CR21","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/ATVBAHA.118.310946","volume":"38","author":"I Muthuramu","year":"2018","unstructured":"Muthuramu, I. et al. Hepatocyte-Specific SR-BI Gene Transfer Corrects Cardiac Dysfunction in Scarb1-Deficient Mice and Improves Pressure Overload-Induced Cardiomyopathy. Arterioscler Thromb Vasc Biol 38, 2028\u20132040, https:\/\/doi.org\/10.1161\/ATVBAHA.118.310946 (2018).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"65255_CR22","doi-asserted-by":"publisher","unstructured":"Amin, R. et al. Selective HDL-Raising Human Apo A-I Gene Therapy Counteracts Cardiac Hypertrophy, Reduces Myocardial Fibrosis, and Improves Cardiac Function in Mice with Chronic Pressure Overload. Int J Mol Sci 18, https:\/\/doi.org\/10.3390\/ijms18092012 (2017).","DOI":"10.3390\/ijms18092012"},{"key":"65255_CR23","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1111\/bph.14463","volume":"175","author":"JP Aboumsallem","year":"2018","unstructured":"Aboumsallem, J. P. et al. Successful treatment of established heart failure in mice with recombinant HDL (Milano). Br J Pharmacol 175, 4167\u20134182, https:\/\/doi.org\/10.1111\/bph.14463 (2018).","journal-title":"Br J Pharmacol"},{"key":"65255_CR24","doi-asserted-by":"publisher","unstructured":"Mishra, M. et al. (Milano) Treatment Efficaciously Reverses Heart Failure with Preserved Ejection Fraction in Mice. Int J Mol Sci 19, https:\/\/doi.org\/10.3390\/ijms19113399 (2018).","DOI":"10.3390\/ijms19113399"},{"key":"65255_CR25","doi-asserted-by":"publisher","unstructured":"Aboumsallem, J. P., Muthuramu, I., Mishra, M., Kempen, H. & De Geest, B. Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice. Int J Mol Sci 20, https:\/\/doi.org\/10.3390\/ijms20061273 (2019).","DOI":"10.3390\/ijms20061273"},{"key":"65255_CR26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/ATVBAHA.115.307052","volume":"36","author":"HJ Kempen","year":"2016","unstructured":"Kempen, H. J. et al. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano\/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients. Arterioscler Thromb Vasc Biol 36, 736\u2013742, https:\/\/doi.org\/10.1161\/ATVBAHA.115.307052 (2016).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"65255_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2016.10.042","volume":"255","author":"HJ Kempen","year":"2016","unstructured":"Kempen, H. J. et al. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano\/POPC) in healthy volunteers and stable coronary artery disease patients. Atherosclerosis 255, 17\u201324, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.042 (2016).","journal-title":"Atherosclerosis"},{"key":"65255_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ehjcvp\/pvv041","volume":"2","author":"DG Kallend","year":"2016","unstructured":"Kallend, D. G. et al. A single infusion of MDCO-216 (ApoA-1 Milano\/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. Eur Heart J Cardiovasc Pharmacother 2, 23\u201329, https:\/\/doi.org\/10.1093\/ehjcvp\/pvv041 (2016).","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"65255_CR29","doi-asserted-by":"publisher","unstructured":"Reijers, J. A. A. et al. MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216. Cardiovasc Drugs Ther, https:\/\/doi.org\/10.1007\/s10557-017-6746-x (2017).","DOI":"10.1007\/s10557-017-6746-x"},{"key":"65255_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11897-017-0343-y","volume":"14","author":"N Suthahar","year":"2017","unstructured":"Suthahar, N., Meijers, W. C., Sillje, H. H. W. & de Boer, R. A. From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. Curr Heart Fail Rep 14, 235\u2013250, https:\/\/doi.org\/10.1007\/s11897-017-0343-y (2017).","journal-title":"Curr Heart Fail Rep"},{"key":"65255_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11906-013-0354-3","volume":"15","author":"F Azibani","year":"2013","unstructured":"Azibani, F., Fazal, L., Chatziantoniou, C., Samuel, J. L. & Delcayre, C. Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr Hypertens Rep 15, 395\u2013400, https:\/\/doi.org\/10.1007\/s11906-013-0354-3 (2013).","journal-title":"Curr Hypertens Rep"},{"key":"65255_CR32","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/CIRCHEARTFAILURE.114.001279","volume":"7","author":"K Tanaka","year":"2014","unstructured":"Tanaka, K. et al. Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ Heart Fail 7, 976\u2013985, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001279 (2014).","journal-title":"Circ Heart Fail"},{"key":"65255_CR33","doi-asserted-by":"publisher","first-page":"e002724","DOI":"10.1161\/CIRCHEARTFAILURE.115.002724","volume":"9","author":"M Valero-Mu\u00f1oz","year":"2016","unstructured":"Valero-Mu\u00f1oz, M. et al. Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. Circ Heart Fail 9, e002724, https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002724 (2016).","journal-title":"Circ Heart Fail"},{"key":"65255_CR34","doi-asserted-by":"publisher","first-page":"H587","DOI":"10.1152\/ajpheart.00298.2012","volume":"303","author":"AG Garcia","year":"2012","unstructured":"Garcia, A. G. et al. Interferon-\u03b3 ablation exacerbates myocardial hypertrophy in diastolic heart failure. Am J Physiol Heart Circ Physiol 303, H587\u2013596, https:\/\/doi.org\/10.1152\/ajpheart.00298.2012 (2012).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"65255_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13069-015-0023-z","volume":"8","author":"AM Murphy","year":"2015","unstructured":"Murphy, A. M., Wong, A. L. & Bezuhly, M. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis Tissue Repair 8, 7, https:\/\/doi.org\/10.1186\/s13069-015-0023-z (2015).","journal-title":"Fibrogenesis Tissue Repair"},{"key":"65255_CR36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1161\/HYPERTENSIONAHA.111.183913","volume":"59","author":"PM Becher","year":"2012","unstructured":"Becher, P. M. et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and \u03b2-receptor blockade. Hypertension 59, 949\u2013957, https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.183913 (2012).","journal-title":"Hypertension"},{"key":"65255_CR37","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.jacc.2014.02.572","volume":"63","author":"CE Murdoch","year":"2014","unstructured":"Murdoch, C. E. et al. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 63, 2734\u20132741, https:\/\/doi.org\/10.1016\/j.jacc.2014.02.572 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR38","doi-asserted-by":"publisher","first-page":"H339","DOI":"10.1152\/ajpheart.00742.2014","volume":"308","author":"DJ Glenn","year":"2015","unstructured":"Glenn, D. J. et al. Cardiac steatosis potentiates angiotensin II effects in the heart. Am J Physiol Heart Circ Physiol 308, H339\u2013350, https:\/\/doi.org\/10.1152\/ajpheart.00742.2014 (2015).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"65255_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1161\/01.CIR.104.3.346","volume":"104","author":"S Ichihara","year":"2001","unstructured":"Ichihara, S. et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104, 346\u2013351, https:\/\/doi.org\/10.1161\/01.CIR.104.3.346 (2001).","journal-title":"Circulation"},{"key":"65255_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajpath.2015.09.010","volume":"186","author":"Y Shen","year":"2016","unstructured":"Shen, Y. et al. Granzyme B Deficiency Protects against Angiotensin II-Induced Cardiac Fibrosis. Am J Pathol 186, 87\u2013100, https:\/\/doi.org\/10.1016\/j.ajpath.2015.09.010 (2016).","journal-title":"Am J Pathol"},{"key":"65255_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/gtc.12055","volume":"18","author":"E Matsumoto","year":"2013","unstructured":"Matsumoto, E. et al. Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16. Genes Cells 18, 544\u2013553, https:\/\/doi.org\/10.1111\/gtc.12055 (2013).","journal-title":"Genes Cells"},{"key":"65255_CR42","doi-asserted-by":"publisher","first-page":"H771","DOI":"10.1152\/ajpheart.00282.2015","volume":"309","author":"JA Regan","year":"2015","unstructured":"Regan, J. A. et al. A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. Am J Physiol Heart Circ Physiol 309, H771\u2013778, https:\/\/doi.org\/10.1152\/ajpheart.00282.2015 (2015).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"65255_CR43","doi-asserted-by":"publisher","first-page":"H1103","DOI":"10.1152\/ajpheart.00636.2012","volume":"304","author":"J Mori","year":"2013","unstructured":"Mori, J. et al. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol 304, H1103\u20131113, https:\/\/doi.org\/10.1152\/ajpheart.00636.2012 (2013).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"65255_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FJC.0b013e31815bb629","volume":"51","author":"Z Xu","year":"2008","unstructured":"Xu, Z. et al. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol 51, 62\u201370, https:\/\/doi.org\/10.1097\/FJC.0b013e31815bb629 (2008).","journal-title":"J Cardiovasc Pharmacol"},{"key":"65255_CR45","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1113\/expphysiol.2011.057612","volume":"96","author":"H Peng","year":"2011","unstructured":"Peng, H. et al. Angiotensin II-induced dilated cardiomyopathy in Balb\/c but not C57BL\/6J mice. Exp Physiol 96, 756\u2013764, https:\/\/doi.org\/10.1113\/expphysiol.2011.057612 (2011).","journal-title":"Exp Physiol"},{"key":"65255_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amjcard.2007.11.012","volume":"101","author":"A Martinez-Rumayor","year":"2008","unstructured":"Martinez-Rumayor, A., Richards, A. M., Burnett, J. C. & Januzzi, J. L. Jr. Biology of the natriuretic peptides. Am J Cardiol 101, 3\u20138, https:\/\/doi.org\/10.1016\/j.amjcard.2007.11.012 (2008).","journal-title":"Am J Cardiol"},{"key":"65255_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/hrt.2005.071233","volume":"92","author":"M Weber","year":"2006","unstructured":"Weber, M. & Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92, 843\u2013849, https:\/\/doi.org\/10.1136\/hrt.2005.071233 (2006).","journal-title":"Heart"},{"key":"65255_CR48","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jch.12546","volume":"17","author":"C Bleakley","year":"2015","unstructured":"Bleakley, C., Hamilton, P. K., Pumb, R., Harbinson, M. & McVeigh, G. E. Endothelial Function in Hypertension: Victim or Culprit? J Clin Hypertens (Greenwich) 17, 651\u2013654, https:\/\/doi.org\/10.1111\/jch.12546 (2015).","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"65255_CR49","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2174\/1566524013666131118113927","volume":"14","author":"SC Gordts","year":"2014","unstructured":"Gordts, S. C., Singh, N., Muthuramu, I. & De Geest, B. Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions. Curr Mol Med 14, 481\u2013503, https:\/\/doi.org\/10.2174\/1566524013666131118113927 (2014).","journal-title":"Curr Mol Med"},{"key":"65255_CR50","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/187153012800493521","volume":"12","author":"F Spillmann","year":"2012","unstructured":"Spillmann, F., Van Linthout, S. & Tschope, C. Cardiac effects of HDL and its components on diabetic cardiomyopathy. Endocr Metab Immune Disord Drug Targets 12, 132\u2013147, https:\/\/doi.org\/10.2174\/187153012800493521 (2012).","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"65255_CR51","doi-asserted-by":"crossref","unstructured":"Van Linthout, S. et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 53, 682-687, HYPERTENSIONAHA.108.118919[pii]10.1161\/HYPERTENSIONAHA.108.118919 (2009).","DOI":"10.1161\/HYPERTENSIONAHA.108.118919"},{"key":"65255_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbrc.2010.11.037","volume":"404","author":"L Lin","year":"2011","unstructured":"Lin, L. et al. High density lipoprotein downregulates angiotensin II type 1 receptor and inhibits angiotensin II-induced cardiac hypertrophy. Biochem Biophys Res Commun 404, 28\u201333, https:\/\/doi.org\/10.1016\/j.bbrc.2010.11.037 (2011).","journal-title":"Biochem Biophys Res Commun"},{"key":"65255_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12950-016-0131-6","volume":"13","author":"F Spillmann","year":"2016","unstructured":"Spillmann, F. et al. Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob\/ob mice. J Inflamm (Lond) 13, 25, https:\/\/doi.org\/10.1186\/s12950-016-0131-6 (2016).","journal-title":"J Inflamm (Lond)"},{"key":"65255_CR54","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1161\/ATVBAHA.115.305887","volume":"35","author":"F Spillmann","year":"2015","unstructured":"Spillmann, F., Miteva, K., Pieske, B., Tschope, C. & Van Linthout, S. High-Density Lipoproteins Reduce Endothelial-to-Mesenchymal Transition. Arteriosclerosis, thrombosis, and vascular biology 35, 1774\u20131777, https:\/\/doi.org\/10.1161\/ATVBAHA.115.305887 (2015).","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"65255_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jacc.2010.11.072","volume":"58","author":"HM Den Ruijter","year":"2011","unstructured":"Den Ruijter, H. M. et al. Reconstituted high-density lipoprotein shortens cardiac repolarization. J Am Coll Cardiol 58, 40\u201344, https:\/\/doi.org\/10.1016\/j.jacc.2010.11.072 (2011).","journal-title":"J Am Coll Cardiol"},{"key":"65255_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12551-014-0159-x","volume":"7","author":"M Balycheva","year":"2015","unstructured":"Balycheva, M., Faggian, G., Glukhov, A. V. & Gorelik, J. Microdomain-specific localization of functional ion channels in cardiomyocytes: an emerging concept of local regulation and remodelling. Biophys Rev 7, 43\u201362, https:\/\/doi.org\/10.1007\/s12551-014-0159-x (2015).","journal-title":"Biophys Rev"},{"key":"65255_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-3-319-09665-0_6","volume":"224","author":"JR Nofer","year":"2015","unstructured":"Nofer, J. R. Signal transduction by HDL: agonists, receptors, and signaling cascades. Handb Exp Pharmacol 224, 229\u2013256, https:\/\/doi.org\/10.1007\/978-3-319-09665-0_6 (2015).","journal-title":"Handb Exp Pharmacol"},{"key":"65255_CR58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00395-013-0359-8","volume":"108","author":"AD Hafstad","year":"2013","unstructured":"Hafstad, A. D., Nabeebaccus, A. A. & Shah, A. M. Novel aspects of ROS signalling in heart failure. Basic Res Cardiol 108, 359, https:\/\/doi.org\/10.1007\/s00395-013-0359-8 (2013).","journal-title":"Basic Res Cardiol"},{"key":"65255_CR59","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1161\/01.RES.0000187457.24338.3D","volume":"97","author":"I Cucoranu","year":"2005","unstructured":"Cucoranu, I. et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97, 900\u2013907, https:\/\/doi.org\/10.1161\/01.RES.0000187457.24338.3D (2005).","journal-title":"Circ Res"},{"key":"65255_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11010-008-9803-8","volume":"317","author":"W Zhao","year":"2008","unstructured":"Zhao, W., Zhao, T., Chen, Y., Ahokas, R. A. & Sun, Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 317, 43\u201350, https:\/\/doi.org\/10.1007\/s11010-008-9803-8 (2008).","journal-title":"Mol Cell Biochem"},{"key":"65255_CR61","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1194\/jlr.M033779","volume":"54","author":"HJ Kempen","year":"2013","unstructured":"Kempen, H. J. et al. Effect of repeated apoA-IMilano\/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. J Lipid Res 54, 2341\u20132353, https:\/\/doi.org\/10.1194\/jlr.M033779 (2013).","journal-title":"J Lipid Res"},{"key":"65255_CR62","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00109-015-1281-3","volume":"93","author":"I Muthuramu","year":"2015","unstructured":"Muthuramu, I. et al. Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. J Mol Med 93, 609\u2013618, https:\/\/doi.org\/10.1007\/s00109-015-1281-3 (2015).","journal-title":"J Mol Med"},{"key":"65255_CR63","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/ijms18071565","volume":"18","author":"I Muthuramu","year":"2017","unstructured":"Muthuramu, I. et al. Coconut Oil Aggravates Pressure Overload-Induced Cardiomyopathy without Inducing Obesity, Systemic Insulin Resistance, or Cardiac Steatosis. Int J Mol Sci 18, 1565, https:\/\/doi.org\/10.3390\/ijms18071565 (2017).","journal-title":"Int J Mol Sci"},{"key":"65255_CR64","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01002772","volume":"11","author":"LC Junqueira","year":"1979","unstructured":"Junqueira, L. C., Bignolas, G. & Brentani, R. R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 11, 447\u2013455, https:\/\/doi.org\/10.1007\/BF01002772 (1979).","journal-title":"Histochem J"},{"key":"65255_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/gt.2011.147","volume":"19","author":"E Van Craeyveld","year":"2012","unstructured":"Van Craeyveld, E., Jacobs, F., Gordts, S. C. & De Geest, B. Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther 19, 860\u2013871, https:\/\/doi.org\/10.1038\/gt.2011.147 (2012).","journal-title":"Gene Ther"},{"key":"65255_CR66","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/gt.2013.30","volume":"20","author":"SC Gordts","year":"2013","unstructured":"Gordts, S. C. et al. Beneficial effects of selective HDL-raising gene transfer on survival, cardiac remodelling and cardiac function after myocardial infarction in mice. Gene Ther 20, 1053\u20131061, https:\/\/doi.org\/10.1038\/gt.2013.30 (2013).","journal-title":"Gene Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65255-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65255-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65255-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:26:06Z","timestamp":1670325966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65255-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65255"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65255-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8382"}}